Axis™ Allograft Dermis for Female Pelvic Floor Repair: a Prospective Post Market Study

Sponsor
Coloplast A/S (Industry)
Overall Status
Completed
CT.gov ID
NCT01541748
Collaborator
(none)
74
5
84.3
14.8
0.2

Study Details

Study Description

Brief Summary

This study is a prospective, single arm, multi-center, post-market study to evaluate the efficacy of Axis™ Allograft Dermis used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.

Condition or Disease Intervention/Treatment Phase
  • Other: Axis

Detailed Description

The study population will be adult female patients with pelvic organ prolapse, POP-Q Stage ≥ 2 that are clinically indicated for surgical intervention with Axis Allograft Dermis in the anterior, posterior or combined (anterior and posterior) compartments.

Study Design

Study Type:
Observational
Actual Enrollment :
74 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Axis™ Allograft Dermis for Female Pelvic Floor Repair: a Prospective Post Market Study
Study Start Date :
Nov 1, 2011
Actual Primary Completion Date :
Nov 11, 2018
Actual Study Completion Date :
Nov 11, 2018

Arms and Interventions

Arm Intervention/Treatment
AXIS Allograft Dermis

Participants receiving AXIS Allograft Dermis for anterior, posterior or combined (anterior and posterior) female pelvic floor repair.

Other: Axis
Coloplast's Axis™ Allograft Dermis is used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.

Outcome Measures

Primary Outcome Measures

  1. Percentage of Participants With POP-Q Stage Improvement Assessed by POP-Q Stage Improvement Based Upon Grading of Prolapse of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Compared Between Baseline and One Year. [1 year]

    The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline

Secondary Outcome Measures

  1. Percentage of Participants With POP-Q Stage Improvement Assessed by POP-Q Stage Improvement Based Upon Grading of Prolapse of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Compared Between Baseline and Six Weeks [6 weeks]

    The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline

  2. Percentage of Participants With POP-Q Stage Improvement After POP Repair With Axis Assessed by POP-Q Stage Improvement Based Upon Prolapse Grading of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Between Baseline and Six Months [6 months]

    The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline

  3. Percentage of Participants With POP-Q Stage Improvement Assessed by POP-Q Stage Improvement Based Upon Grading of Prolapse of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Compared Between Baseline at 24 Months [24 months]

    The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline

  4. Percentage of Participants With POP-Q Stage Improvement After POP Repair With Axis Assessed by POP-Q Stage Improvement Based Upon Prolapse Grading of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Between Baseline at 36 Months [36 months]

    The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline

  5. Change in Participant Sexual Satisfaction From Baseline After Pelvic Organ Prolapse Repair With Axis Allograft Dermis Measured by Participant Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) at 6 Months [Baseline and 6 months]

    The PISQ-12 is the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12). Sexual Function in women after pelvic organ prolapse repair with Axis Allograft Dermis measured by PISQ-12 at 6 months. The scores range from 0-48 with lower scores indicating better sexual function. Scores are calculated by totaling the scores for each question with (4) always, (3) usually, (2) sometimes, (1) seldom, and (0) never. Reverse scoring is used for items 1, 2, 3 and 4. The short form questionnaire can be used with up to two missing responses. To handle missing values, the sum is calculated by multiplying the number of items by the mean of the answered items.

  6. Change in Patient Sexual Satisfaction From Baseline After Pelvic Organ Prolapse Repair With Axis Allograft Dermis Measured by Participant Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) at 12 Months [Baseline and 12 months]

    The PISQ-12 is the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12). Sexual Function in women after pelvic organ prolapse repair with Axis Allograft Dermis measured by PISQ-12 at 6 months. The scores range from 0-48 with lower scores indicating better sexual function. Scores are calculated by totaling the scores for each question with (4) always, (3) usually, (2) sometimes, (1) seldom, and (0) never. Reverse scoring is used for items 1, 2, 3 and 4. The short form questionnaire can be used with up to two missing responses. To handle missing values, the sum is calculated by multiplying the number of items by the mean of the answered items.

  7. Change in Patient Sexual Satisfaction From Baseline After Pelvic Organ Prolapse Repair With Axis Allograft Dermis Measured by Participant Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) at 24 Months [Baseline and 24 months]

    The PISQ-12 is the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12). Sexual Function in women after pelvic organ prolapse repair with Axis Allograft Dermis measured by PISQ-12 at 6 months. The scores range from 0-48 with lower scores indicating better sexual function. Scores are calculated by totaling the scores for each question with (4) always, (3) usually, (2) sometimes, (1) seldom, and (0) never. Reverse scoring is used for items 1, 2, 3 and 4. The short form questionnaire can be used with up to two missing responses. To handle missing values, the sum is calculated by multiplying the number of items by the mean of the answered items.

  8. Change in Patient Sexual Satisfaction From Baseline After Pelvic Organ Prolapse Repair With Axis Allograft Dermis Measured by Participant Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) at 36 Months [Baseline and 36 months]

    The PISQ-12 is the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12). Sexual Function in women after pelvic organ prolapse repair with Axis Allograft Dermis measured by PISQ-12 at 6 months. The scores range from 0-48 with lower scores indicating better sexual function. Scores are calculated by totaling the scores for each question with (4) always, (3) usually, (2) sometimes, (1) seldom, and (0) never. Reverse scoring is used for items 1, 2, 3 and 4. The short form questionnaire can be used with up to two missing responses. To handle missing values, the sum is calculated by multiplying the number of items by the mean of the answered items.

  9. Percentage of Participants Responding "Very Much Better" or "Much Better" on Patient Global Impression of Improvement for Urogenital Prolapse (PGI-I) at 12 Months [12 months]

    The PGI-I Index consists of one question and was collected at 12 months. The question is "Check the box that best describes how your condition is now, compared with how it was before you had the operation." There are seven possible responses including, "very much better," "much better," "a little better," "no change," "a little worse," "much worse," and "very much worse and the subject chooses one response.

  10. Percentage of Participants Responding "Very Much Better" or "Much Better" on Patient Global Impression of Improvement for Urogenital Prolapse (PGI-I) at 24 Months [24 month]

    The PGI-I Index consists of one question and was collected at 24 months. The question is "Check the box that best describes how your condition is now, compared with how it was before you had the operation." There are seven possible responses including, "very much better," "much better," "a little better," "no change," "a little worse," "much worse," and "very much worse and the subject chooses one response.

  11. Percentage of Participants Responding "Very Much Better" or "Much Better" on Patient Global Impression of Improvement for Urogenital Prolapse (PGI-I) at 36 Months [36 months]

    The PGI-I Index consists of one question and was collected at 36 months. The question is "Check the box that best describes how your condition is now, compared with how it was before you had the operation." There are seven possible responses including, "very much better," "much better," "a little better," "no change," "a little worse," "much worse," and "very much worse and the subject chooses one response.

  12. Change in Pelvic/Bladder Pain With Daily Activity Visual Analog Scale (VAS) Questionnaire From Baseline to 6 Weeks, 6 Months, 12 Months, 24 Months, 36 Months [Baseline and 6 weeks, 6 months, 12 months, 24 months, 36 months]

    The Visual analog scales (VAS) Questionnaire is a questionnaire that asks the participant to mark a place on a scale that aligns with their level of pain. Participants were asked to make a vertical mark on a 10 centimeter line marked with "No Pain" and "Worst Pain" at each end and the line was measured to the tenths decimal place. A lower score indicates less pain.

  13. Change in Pelvic/Bladder Pain With Sexual Activity Visual Analog Scale (VAS) Questionnaire From Baseline to 6 Weeks, 6 Months, 12 Months, 24 Months, 36 Months [Baseline and 6 weeks, 6 months, 1 year, 2 years, 3 years]

    The Visual analog scales (VAS) Questionnaire is a questionnaire that asks the participant to mark a place on a scale that aligns with their level of pain. Participants were asked to make a vertical mark on a 10 centimeter line with the left end marker labeled "No Pain" and the right end marker labeled "Worst Pain." The line was measured to the tenths decimal place. Zero was the minimum value and 10 was the maximum value. Higher scores indicated a greater amount of pain.

  14. Percentage of Participants Who Had Surgical Revision of the Index Prolapse Compartment(s) After Pelvic Organ Prolapse Repair With Axis [3 year]

    Percentage of participants who had surgical revision of the index prolapse compartment(s) after pelvic organ prolapse repair with Axis from the time of the index procedure to the end of study visit.

  15. Ratings for the Validated Surgical Satisfaction Questionnaire (SSQ-8) in Women Following Surgery to Correct Pelvic Organ Prolapse Repair With Axis Allograft Dermis at the 6 Week, 6 Month, 12 Month, 24 Month, and 36 Month Visits. [6 week, 6 month, 12 month, 24 month, and 36 month visits]

    The Surgical Satisfaction Questionnaire (SSQ-8) is a validated questionnaire consisting of eight questions assessing participant satisfaction with the results of their surgery to correct urinary incontinence and/or pelvic organ prolapse. Scoring is implemented with the mean average of the 8 scores multiplied by 25, yielding a potential range of scores from 0 to 100. The higher the score is, the greater the degree of surgical satisfaction.

  16. Change in Pelvic Floor Distress Inventory (PFDI-20) Questionnaire After Pelvic Organ Prolapse Repair With Axis Allograft Dermis From Baseline to 6 Weeks, 6 Months, 12 Months, 24 Months, and 36 Months [Baseline and 6 weeks, 6 months, 12 Months, 24 Months, 36 Months]

    The Pelvic Floor Distress Inventory Questionnaire (PFDI-20) is a questionnaire with 20 questions that measures symptom distress and impact of health-related quality of life. The PFDI-20 has three scales: Pelvic Organ Prolapse Distress Inventory (POPDI-6), Colorectal-Anal Distress Inventory (CRADI-8), and Urinary Distress Inventory (UDI-6). Each of the 3 scales of the PFDI-20 is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 to 300. Higher scores indicate more distress.

  17. Change in the Participants Response on the Pelvic Floor Impact Questionnaire (PFIQ) From Baseline to 6 Weeks, 6 Months, 12 Months, 24 Months, 36 Months [Baseline and 6 weeks, 6 months, 12 Months, 24 Months, 36 Months]

    The Pelvic Floor Impact Questionnaire (PFIQ) measures impact of bladder, bowel, and vaginal symptoms on daily physical activity, travel, social/relationships, and emotional health. The PFIQ-7 has three scales: the Urinary Impact Questionnaire (UIQ-7), the Colorectal-Anal Impact Questionnaire (CRAIQ-7), and the Pelvic Organ Prolapse Impact Questionnaire (POPIQ-7). Response options range from 0 ("not at all") to 3 ("quite a bit"). Per scale, the mean score of answered items is multiplied by 33.3 to obtain the scale score (range 0-100) [4]. Summary scores are calculated by adding up the scale scores (range 0-300) [4]. Higher scores indicate more impact on daily activity.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult female at least 18 years of age.

  • Willing and able to provide written informed consent.

  • Confirmed pelvic organ prolapse (POP) of Stage 2 or higher as determined by POP-Q prolapse grading requiring surgical intervention in the anterior, posterior or combined (anterior and posterior) compartment.

  • Willing and able to complete all follow-up visits and procedures indicated in this protocol.

Exclusion Criteria:
  • Concurrent surgical treatment of pelvic organ prolapse using anything other than the Axis Dermis.[Note: concurrent mid-urethral sling placement for treatment of stress urinary incontinence is allowed].

  • Confirmed Stage 2 or higher prolapse as determined by POP-Q prolapse grading for a compartment that is not being repaired in the same procedure. (Concurrent POP-Q Stage 1 repair is at the physician's discretion.)

  • Previous pelvic organ prolapse repair using biologic, or synthetic grafts. [Note: previous mid-urethral sling for treatment of stress urinary incontinence is allowed]

  • Pregnant or a desire to become pregnant in the future.

  • Previous radiation or other treatments for cancer in the pelvic area.

  • Severe urogenital atrophy.

  • Immunosuppression and/or current systemic steroid user.

  • Any contraindication to the surgical procedure.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cleveland Clinic Florida Weston Florida United States 33331
2 Boston Urogynecology Associates Cambridge Massachusetts United States 02138
3 Female Pelvic Medicine and Urogynecology Institute of MI/Grand Rapids Women's Health Grand Rapids Michigan United States 49503
4 The Institute for Female Pelvic Medicine and Reconstructive Surgery Allentown Pennsylvania United States 18103
5 Philadelphia Urosurgical Associates Philadelphia Pennsylvania United States 19107

Sponsors and Collaborators

  • Coloplast A/S

Investigators

  • Principal Investigator: Kristine Whitmore, MD, Virtua Female Pelvic Medicine

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Coloplast A/S
ClinicalTrials.gov Identifier:
NCT01541748
Other Study ID Numbers:
  • CP009SU
First Posted:
Mar 1, 2012
Last Update Posted:
Jun 30, 2020
Last Verified:
Jun 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

Participant Flow

Recruitment Details
Pre-assignment Detail Seventy-four subjects were consented. Five subjects did not meet inclusion/exclusion criteria and one subject was not implanted with a study device.
Arm/Group Title Axis Allograft Dermis
Arm/Group Description Subjects with clinically significant pelvic organ prolapse Stage greater than or equal to 2, with surgical intervention using Axis device in the anterior, posterior, or combined (anterior and posterior) compartments.
Period Title: Overall Study
STARTED 74
COMPLETED 43
NOT COMPLETED 31

Baseline Characteristics

Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair.
Overall Participants 74
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]
60.4
(11.7)
Sex: Female, Male (Count of Participants)
Female
74
100%
Male
0
0%
Race and Ethnicity Not Collected (Count of Participants)
Region of Enrollment (participants) [Number]
United States
74
100%
BMI (Kg/m^2) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Kg/m^2]
27.9
(4.8)
Diabetes (Count of Participants)
Count of Participants [Participants]
3
4.1%

Outcome Measures

1. Primary Outcome
Title Percentage of Participants With POP-Q Stage Improvement Assessed by POP-Q Stage Improvement Based Upon Grading of Prolapse of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Compared Between Baseline and One Year.
Description The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline
Time Frame 1 year

Outcome Measure Data

Analysis Population Description
Participants with clinically significant pelvic organ prolapse of Stage 2 or higher with surgical intervention using Axis Allograft Dermis in the anterior, posterior or combined (anterior and posterior) compartments.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair.
Measure Participants 46
Cured
35
47.3%
Improved
4
5.4%
Failed
7
9.5%
2. Secondary Outcome
Title Percentage of Participants With POP-Q Stage Improvement Assessed by POP-Q Stage Improvement Based Upon Grading of Prolapse of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Compared Between Baseline and Six Weeks
Description The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline
Time Frame 6 weeks

Outcome Measure Data

Analysis Population Description
Participants with clinically significant pelvic organ prolapse of Stage 2 or higher with surgical intervention using Axis Allograft Dermis in the anterior, posterior or combined (anterior and posterior) compartments.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair.
Measure Participants 65
Cured
63
85.1%
Improved
1
1.4%
Failed
1
1.4%
3. Secondary Outcome
Title Percentage of Participants With POP-Q Stage Improvement After POP Repair With Axis Assessed by POP-Q Stage Improvement Based Upon Prolapse Grading of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Between Baseline and Six Months
Description The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline
Time Frame 6 months

Outcome Measure Data

Analysis Population Description
Participants with clinically significant pelvic organ prolapse of Stage 2 or higher with surgical intervention using Axis Allograft Dermis in the anterior, posterior or combined (anterior and posterior) compartments
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair at 6 months
Measure Participants 57
Cured
46
62.2%
Improved
5
6.8%
Failed
6
8.1%
4. Secondary Outcome
Title Percentage of Participants With POP-Q Stage Improvement Assessed by POP-Q Stage Improvement Based Upon Grading of Prolapse of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Compared Between Baseline at 24 Months
Description The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline
Time Frame 24 months

Outcome Measure Data

Analysis Population Description
Participants with clinically significant pelvic organ prolapse of Stage 2 or higher with surgical intervention using Axis Allograft Dermis in the anterior, posterior or combined (anterior and posterior) compartments.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair.
Measure Participants 46
Cured
36
48.6%
Improved
2
2.7%
Failed
8
10.8%
5. Secondary Outcome
Title Percentage of Participants With POP-Q Stage Improvement After POP Repair With Axis Assessed by POP-Q Stage Improvement Based Upon Prolapse Grading of the Anterior, Posterior, or Combined Anterior and Posterior Compartments Between Baseline at 36 Months
Description The Pelvic Organ Prolapse Quantification system (POP-Q) is used to measure pelvic organ prolapse. POP-Q Stages are: Stage 0: No prolapse is demonstrated Stage 1: The criteria for stage 0 are not met, but the most distal portion of the prolapse is greater than 1 cm above the level of the hymen Stage 2: The most distal portion of the prolapse is greater than or equal to 1 centimeter proximal to or distal to the plane of the hymen Stage 3: The most distal portion of the prolapse is greater than 1 centimeter below the plan of the hymen but protrudes no further than 2 centimeters less that the total vaginal length in centimeters Stage 4: The distal portion of the prolapse protrudes to at least (TVL-2) centimeters. Improvement at one year is categorized as follows: Cured: Pop-Q Stage reduced to 0 or 1, or improved by 2 stages from baseline Improved: POP-Q Stage > 1, but improved by 1 stage from baseline Failed: POP-Q Stage stayed the same or increased in severity from baseline
Time Frame 36 months

Outcome Measure Data

Analysis Population Description
Participants with clinically significant pelvic organ prolapse of Stage 2 or higher with surgical intervention using Axis Allograft Dermis in the anterior, posterior or combined (anterior and posterior) compartments.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair.
Measure Participants 43
Cured
27
36.5%
Improved
7
9.5%
Failed
9
12.2%
6. Secondary Outcome
Title Change in Participant Sexual Satisfaction From Baseline After Pelvic Organ Prolapse Repair With Axis Allograft Dermis Measured by Participant Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) at 6 Months
Description The PISQ-12 is the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12). Sexual Function in women after pelvic organ prolapse repair with Axis Allograft Dermis measured by PISQ-12 at 6 months. The scores range from 0-48 with lower scores indicating better sexual function. Scores are calculated by totaling the scores for each question with (4) always, (3) usually, (2) sometimes, (1) seldom, and (0) never. Reverse scoring is used for items 1, 2, 3 and 4. The short form questionnaire can be used with up to two missing responses. To handle missing values, the sum is calculated by multiplying the number of items by the mean of the answered items.
Time Frame Baseline and 6 months

Outcome Measure Data

Analysis Population Description
The 19 participants who completed the PISQ-12 at the 6 month follow up visit.
Arm/Group Title Axis Allograft Dermis
Arm/Group Description Participants with clinically significant pelvic organ prolapse Stage greater than or equal to 2, with surgical intervention using Axis device in the anterior, posterior, or combined (anterior and posterior) compartments.
Measure Participants 19
6 months
-3.1
(10.4)
Baseline
16.8
(8.1)
7. Secondary Outcome
Title Change in Patient Sexual Satisfaction From Baseline After Pelvic Organ Prolapse Repair With Axis Allograft Dermis Measured by Participant Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) at 12 Months
Description The PISQ-12 is the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12). Sexual Function in women after pelvic organ prolapse repair with Axis Allograft Dermis measured by PISQ-12 at 6 months. The scores range from 0-48 with lower scores indicating better sexual function. Scores are calculated by totaling the scores for each question with (4) always, (3) usually, (2) sometimes, (1) seldom, and (0) never. Reverse scoring is used for items 1, 2, 3 and 4. The short form questionnaire can be used with up to two missing responses. To handle missing values, the sum is calculated by multiplying the number of items by the mean of the answered items.
Time Frame Baseline and 12 months

Outcome Measure Data

Analysis Population Description
The 17 participants who completed the PISQ-12 at the twelve month follow up visit.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Participants with clinically significant pelvic organ prolapse of Stage 2 or higher with surgical intervention using Axis Allograft Dermis in the anterior and/or posterior compartment.
Measure Participants 17
12 months
-2.9
(6.9)
Baseline
16.8
(8.1)
8. Secondary Outcome
Title Change in Patient Sexual Satisfaction From Baseline After Pelvic Organ Prolapse Repair With Axis Allograft Dermis Measured by Participant Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) at 24 Months
Description The PISQ-12 is the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12). Sexual Function in women after pelvic organ prolapse repair with Axis Allograft Dermis measured by PISQ-12 at 6 months. The scores range from 0-48 with lower scores indicating better sexual function. Scores are calculated by totaling the scores for each question with (4) always, (3) usually, (2) sometimes, (1) seldom, and (0) never. Reverse scoring is used for items 1, 2, 3 and 4. The short form questionnaire can be used with up to two missing responses. To handle missing values, the sum is calculated by multiplying the number of items by the mean of the answered items.
Time Frame Baseline and 24 months

Outcome Measure Data

Analysis Population Description
The 13 participants who completed the PISQ-12 at the 24 month follow up visit.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Participants with clinically significant pelvic organ prolapse of Stage 2 or higher with surgical intervention using Axis Allograft Dermis in the anterior and/or posterior compartment.
Measure Participants 13
Mean (Standard Deviation) [score on a scale]
-2.2
(5.1)
9. Secondary Outcome
Title Change in Patient Sexual Satisfaction From Baseline After Pelvic Organ Prolapse Repair With Axis Allograft Dermis Measured by Participant Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) at 36 Months
Description The PISQ-12 is the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12). Sexual Function in women after pelvic organ prolapse repair with Axis Allograft Dermis measured by PISQ-12 at 6 months. The scores range from 0-48 with lower scores indicating better sexual function. Scores are calculated by totaling the scores for each question with (4) always, (3) usually, (2) sometimes, (1) seldom, and (0) never. Reverse scoring is used for items 1, 2, 3 and 4. The short form questionnaire can be used with up to two missing responses. To handle missing values, the sum is calculated by multiplying the number of items by the mean of the answered items.
Time Frame Baseline and 36 months

Outcome Measure Data

Analysis Population Description
The 19 participants who completed the PISQ-12 at the 36 month follow up visit.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Participants with clinically significant pelvic organ prolapse of Stage 2 or higher with surgical intervention using Axis Allograft Dermis in the anterior and/or posterior compartment.
Measure Participants 19
36 month
11.9
(6.9)
Baseline
16.8
(8.1)
10. Secondary Outcome
Title Percentage of Participants Responding "Very Much Better" or "Much Better" on Patient Global Impression of Improvement for Urogenital Prolapse (PGI-I) at 12 Months
Description The PGI-I Index consists of one question and was collected at 12 months. The question is "Check the box that best describes how your condition is now, compared with how it was before you had the operation." There are seven possible responses including, "very much better," "much better," "a little better," "no change," "a little worse," "much worse," and "very much worse and the subject chooses one response.
Time Frame 12 months

Outcome Measure Data

Analysis Population Description
The 48 participants who completed the PGI-I at the 12 month follow up visit.
Arm/Group Title Axis Allograft Dermis
Arm/Group Description Participants implanted with Axis Allograft Dermis who completed the PGI-I Questionnaire at 12 months.
Measure Participants 48
Number [percentage of participants]
87.5
118.2%
11. Secondary Outcome
Title Percentage of Participants Responding "Very Much Better" or "Much Better" on Patient Global Impression of Improvement for Urogenital Prolapse (PGI-I) at 24 Months
Description The PGI-I Index consists of one question and was collected at 24 months. The question is "Check the box that best describes how your condition is now, compared with how it was before you had the operation." There are seven possible responses including, "very much better," "much better," "a little better," "no change," "a little worse," "much worse," and "very much worse and the subject chooses one response.
Time Frame 24 month

Outcome Measure Data

Analysis Population Description
The 46 participants who completed the PGI-I at the 24 month follow up visit.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description The PGI-I Index consists on one question and was collected at 6 weeks. The question is "Check the box that best describes how your condition is now, compared with how it was before you had the operation." There are seven possible responses including "very much better," "much better," "a little better," "no change," "a little worse," "much worse" and "very much worse" and the subject chooses one response.
Measure Participants 46
Number [percentage of participants]
87.0
117.6%
12. Secondary Outcome
Title Percentage of Participants Responding "Very Much Better" or "Much Better" on Patient Global Impression of Improvement for Urogenital Prolapse (PGI-I) at 36 Months
Description The PGI-I Index consists of one question and was collected at 36 months. The question is "Check the box that best describes how your condition is now, compared with how it was before you had the operation." There are seven possible responses including, "very much better," "much better," "a little better," "no change," "a little worse," "much worse," and "very much worse and the subject chooses one response.
Time Frame 36 months

Outcome Measure Data

Analysis Population Description
The 42 participants who completed the PGI-I at the 36 month follow up visit.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Participants implanted with Axis Allograft Dermis
Measure Participants 42
Number [percentage of participants]
88.1
119.1%
13. Secondary Outcome
Title Change in Pelvic/Bladder Pain With Daily Activity Visual Analog Scale (VAS) Questionnaire From Baseline to 6 Weeks, 6 Months, 12 Months, 24 Months, 36 Months
Description The Visual analog scales (VAS) Questionnaire is a questionnaire that asks the participant to mark a place on a scale that aligns with their level of pain. Participants were asked to make a vertical mark on a 10 centimeter line marked with "No Pain" and "Worst Pain" at each end and the line was measured to the tenths decimal place. A lower score indicates less pain.
Time Frame Baseline and 6 weeks, 6 months, 12 months, 24 months, 36 months

Outcome Measure Data

Analysis Population Description
The participants who completed the VAS Questionnaire for Pelvic/Bladder Pain with Daily Activity at the 6 week, 6 month, 12 month, 24 month, and 36 month visits. Some participants either did not complete the questionnaire or did not complete it correctly and this accounts for the lesser total number of participant questionnaires analyzed.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair.
Measure Participants 61
Baseline
1.7
(2.6)
6 week
-.08
(2.4)
6 month
-1.0
(2.7)
12 month
-1.5
(2.8)
24 month
-1.1
(2.4)
36 month
0.5
(1.6)
14. Secondary Outcome
Title Change in Pelvic/Bladder Pain With Sexual Activity Visual Analog Scale (VAS) Questionnaire From Baseline to 6 Weeks, 6 Months, 12 Months, 24 Months, 36 Months
Description The Visual analog scales (VAS) Questionnaire is a questionnaire that asks the participant to mark a place on a scale that aligns with their level of pain. Participants were asked to make a vertical mark on a 10 centimeter line with the left end marker labeled "No Pain" and the right end marker labeled "Worst Pain." The line was measured to the tenths decimal place. Zero was the minimum value and 10 was the maximum value. Higher scores indicated a greater amount of pain.
Time Frame Baseline and 6 weeks, 6 months, 1 year, 2 years, 3 years

Outcome Measure Data

Analysis Population Description
Participants who completed the VAS Questionnaire for Pelvic/Bladder Pain with Sexual Activity at the 6 week, 6 month, 12 month, 24 month, and 36 month visits. Some participants were not sexually active and this accounts for the lesser total number of participant questionnaires analyzed at certain visit intervals.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair..
Measure Participants 48
Baseline
1.8
(2.9)
6 Week
-0.7
(2.9)
6 Month
-0.3
(3.4)
12 Month
-0.9
(2.9)
24 Month
-1.0
(3.3)
36 Month
-1.5
(3.3)
15. Secondary Outcome
Title Percentage of Participants Who Had Surgical Revision of the Index Prolapse Compartment(s) After Pelvic Organ Prolapse Repair With Axis
Description Percentage of participants who had surgical revision of the index prolapse compartment(s) after pelvic organ prolapse repair with Axis from the time of the index procedure to the end of study visit.
Time Frame 3 year

Outcome Measure Data

Analysis Population Description
The participants who had surgical revision of the index prolapse compartment(s) after pelvic organ prolapse repair with Axis from the time of the index procedure to the end of study visit.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Participants with clinically significant pelvic organ prolapse of Stage 2 or higher with surgical intervention using Axis Allograft Dermis in the anterior, posterior or combined (anterior and posterior) compartments.
Measure Participants 68
Count of Participants [Participants]
0
0%
16. Secondary Outcome
Title Ratings for the Validated Surgical Satisfaction Questionnaire (SSQ-8) in Women Following Surgery to Correct Pelvic Organ Prolapse Repair With Axis Allograft Dermis at the 6 Week, 6 Month, 12 Month, 24 Month, and 36 Month Visits.
Description The Surgical Satisfaction Questionnaire (SSQ-8) is a validated questionnaire consisting of eight questions assessing participant satisfaction with the results of their surgery to correct urinary incontinence and/or pelvic organ prolapse. Scoring is implemented with the mean average of the 8 scores multiplied by 25, yielding a potential range of scores from 0 to 100. The higher the score is, the greater the degree of surgical satisfaction.
Time Frame 6 week, 6 month, 12 month, 24 month, and 36 month visits

Outcome Measure Data

Analysis Population Description
The subjects who completed the SSQ-8 Questionnaire at the 6 week, 6 month, 12 month, 24 month, and 36 month visits.
Arm/Group Title Axis Allograft Dermis
Arm/Group Description Subjects with clinically significant pelvic organ prolapse Stage greater than or equal to 2, with surgical intervention using Axis device in the anterior, posterior, or combined (anterior and posterior) compartments.
Measure Participants 65
6 Weeks
83.2
(15.9)
Month 6
81.7
(20.2)
Month 12
87.9
(13.8)
Month 24
86.8
(14.8)
Month 36
86.2
(17.3)
17. Secondary Outcome
Title Change in Pelvic Floor Distress Inventory (PFDI-20) Questionnaire After Pelvic Organ Prolapse Repair With Axis Allograft Dermis From Baseline to 6 Weeks, 6 Months, 12 Months, 24 Months, and 36 Months
Description The Pelvic Floor Distress Inventory Questionnaire (PFDI-20) is a questionnaire with 20 questions that measures symptom distress and impact of health-related quality of life. The PFDI-20 has three scales: Pelvic Organ Prolapse Distress Inventory (POPDI-6), Colorectal-Anal Distress Inventory (CRADI-8), and Urinary Distress Inventory (UDI-6). Each of the 3 scales of the PFDI-20 is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 to 300. Higher scores indicate more distress.
Time Frame Baseline and 6 weeks, 6 months, 12 Months, 24 Months, 36 Months

Outcome Measure Data

Analysis Population Description
Participants who completed the Pelvic Floor Distress Inventory (PFDI-20) Questionnaire at 6 week, 6 month, 12 Month, 24 Month, 36 Month visits.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair.
Measure Participants 60
Baseline
108.3
(59.6)
6 Week
-58
(61.3)
6 Month
-62.5
(63.4)
12 Month
-69.4
(56.1)
24 Month
-62.0
(63.6)
36 Month
-62.7
(71.3)
18. Secondary Outcome
Title Change in the Participants Response on the Pelvic Floor Impact Questionnaire (PFIQ) From Baseline to 6 Weeks, 6 Months, 12 Months, 24 Months, 36 Months
Description The Pelvic Floor Impact Questionnaire (PFIQ) measures impact of bladder, bowel, and vaginal symptoms on daily physical activity, travel, social/relationships, and emotional health. The PFIQ-7 has three scales: the Urinary Impact Questionnaire (UIQ-7), the Colorectal-Anal Impact Questionnaire (CRAIQ-7), and the Pelvic Organ Prolapse Impact Questionnaire (POPIQ-7). Response options range from 0 ("not at all") to 3 ("quite a bit"). Per scale, the mean score of answered items is multiplied by 33.3 to obtain the scale score (range 0-100) [4]. Summary scores are calculated by adding up the scale scores (range 0-300) [4]. Higher scores indicate more impact on daily activity.
Time Frame Baseline and 6 weeks, 6 months, 12 Months, 24 Months, 36 Months

Outcome Measure Data

Analysis Population Description
Subjects who completed the Pelvic Floor Impact Questionnaire Questionnaire at 6 weeks, 6 month, 12 Month, 24 Month, and 36 Month visits.
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Adult females with POP-Q Stage greater than or equal to 2 receiving AXIS Allograft Dermis for anterior, posterior or combined female pelvic floor repair.
Measure Participants 60
Baseline
65.8
(63.4)
6 Week
-31.5
(56.7)
6 Month
-41.2
(66.5)
12 Month
-46
(72.1)
24 Month
-48.8
(65.9)
36 Month
-44.9
(70.8)

Adverse Events

Time Frame Adverse event data was collected from the index procedure through study completion. Thus, the timeframe duration over which adverse events were collected is three years post index procedure.
Adverse Event Reporting Description
Arm/Group Title AXIS Allograft Dermis
Arm/Group Description Participants implanted with AXIS Allograft Dermis.
All Cause Mortality
AXIS Allograft Dermis
Affected / at Risk (%) # Events
Total 0/68 (0%)
Serious Adverse Events
AXIS Allograft Dermis
Affected / at Risk (%) # Events
Total 1/68 (1.5%)
Infections and infestations
Pelvic abscess. 1/68 (1.5%) 1
Surgical and medical procedures
Hematoma 1/68 (1.5%) 1
Wound dehiscence 1/68 (1.5%) 1
Other (Not Including Serious) Adverse Events
AXIS Allograft Dermis
Affected / at Risk (%) # Events
Total 7/68 (10.3%)
Skin and subcutaneous tissue disorders
Wound dehiscence 4/68 (5.9%) 4
Surgical and medical procedures
Pain (Lasting > 6 weeks post-operatively) 3/68 (4.4%) 3

Limitations/Caveats

The study N was small.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

Results Point of Contact

Name/Title Cathy Bartz
Organization Coloplast
Phone 612-834-3127
Email uscmba@coloplast.com
Responsible Party:
Coloplast A/S
ClinicalTrials.gov Identifier:
NCT01541748
Other Study ID Numbers:
  • CP009SU
First Posted:
Mar 1, 2012
Last Update Posted:
Jun 30, 2020
Last Verified:
Jun 1, 2020